Shares of Johnson & Johnson fell over 2% on Wednesday, hitting nearly one-week lows, despite reporting better-than-expected ...
The Minnesota Vikings face a challenging offseason, with questions surrounding quarterback J.J. McCarthy’s readiness and significant roster changes on the horizon. The 2025 campaign will test the team ...
Minnesota Vikings QB J.J. McCarthy is a relative unknown and suffered a serious knee injury, which has led to questions ...
Johnson & Johnson reported better-than-expected quarterly revenue and profit on higher sales of cancer drugs and some medical devices. But shares slipped 3.2% to $143.35 in Wednesday morning trading, ...
J&J's $132 per-share offer implies 39% premium Deal could kick off spree of activity in sector in 2025 CEO says such large deals not common The deal would help accelerate growth in J&J's drugs ...
Their latest trick has been turning up the heat on speculation the Vikings could deal rookie J.J. McCarthy in the offseason. "They are not trading J.J. McCarthy," Matthew Coller told the Star ...
J.J. Watt with his wife Kealia Watt with his child (Image Credit: Getty Images) J.J. Watt is a name synonymous with NFL greatness. But beyond his legendary football career, his personal life is ...
When the Vikings drafted J.J. McCarthy with the No. 10 pick in last April’s draft, they did so with plans for him to become their starting quarterback when ready. But that was before Darnold ...
J&J Buys Intra-Cellular in $14.6 Billion Deal, Delving Further Into Central Nervous System Disorders
J&J Buys Intra-Cellular in $14.6 Billion Deal, Delving Further Into Central Nervous System Disorders Johnson & Johnson will spend more than $14 billion to delve further into the treatment of ...
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback